AbCellera Biologics Inc. last reported quarterly results on Aug 5, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $4.0 million (-76.3% year over year) and diluted EPS of -$0.18. It usually reports 36–55 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–55 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
4
-76.3%
|
-55
-59.6%
|
-0.18
-50.0%
|
|
May 11, 2026
41 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
8
+96.3%
|
-43
+5.4%
|
-0.14
+6.7%
|
|
Feb 24, 2026
55 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
45
+788.2%
|
-9
+73.9%
|
-0.03
+74.2%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
9
+37.6%
|
-57
-11.8%
|
-0.19
-11.8%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
17
+133.3%
|
-35
+6.0%
|
-0.12
+7.7%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
4
-57.5%
|
-46
-12.3%
|
-0.15
-7.1%
|
|
Feb 27, 2025
58 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
5
-45.0%
|
-34
+27.4%
|
-0.12
+28.7%
|
|
Nov 4, 2024
35 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
7
-1.4%
|
-51
-78.6%
|
-0.17
-70.0%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABCL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver, British Columbia, Canada
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1703057
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.